MARKET

VERV

VERV

Verve Therapeutics, Inc.
NASDAQ
11.12
-0.26
-2.28%
After Hours: 11.11 -0.01 -0.08% 19:58 06/18 EDT
OPEN
11.18
PREV CLOSE
11.38
HIGH
11.26
LOW
11.10
VOLUME
13.07M
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
2.865
MARKET CAP
991.27M
P/E (TTM)
-5.2726
1D
5D
1M
3M
1Y
5Y
1D
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
NASDAQ · 9h ago
J.P. Morgan Remains a Hold on Verve Therapeutics (VERV)
TipRanks · 12h ago
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
Barchart · 1d ago
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Benzinga · 1d ago
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition
TipRanks · 1d ago
SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
NASDAQ · 1d ago
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Benzinga · 1d ago
More
About VERV
Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.

Webull offers Verve Therapeutics Inc stock information, including NASDAQ: VERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERV stock methods without spending real money on the virtual paper trading platform.